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The Old and the New Marschall S. Runge, MD, PhD, Thomas Quertermous, MD, and Edgar Haber, MD T hrombosis of a coronary or cerebral artery is the most common cause of mortality and morbidity in the developed nations. ' The proximate cause is most often atherosclerosis, and the most appropriate intervention is its prevention. Much progress has been made in identifying the risk factors predisposing to atherosclerosis, and, perhaps because of their recognition, a significant decrease in the incidence of both stroke and myocardial infarction has occurred. However, coronary thrombosis remains a major clinical problem. Early dissolution of the thrombus by plasminogen activator therapy has become the most effective means of limiting myocardial damage.
With The surge in interest in the clinical use of plasminogen activators coincides with a new ability to use the tools of molecular biology to understand and modify them. For nearly a decade, the focus of investigation has been on the development of plasminogen activators that could be targeted to the fibrin in a blood clot. Now on the horizon are agents with markedly increased fibrin selectivity and other clinically important modifications such as increased half-life and resistance to inactivation in plasma. Other targets for more selective thrombolysis may well be identified, leading to the development of agents with yet greater specificity and safety.
We begin this review by discussing the basic aspects of thrombolysis, the role of plasminogen in thrombolysis, and the structure and function of the plasminogen activators. We then describe the pharmacologic effects of plasminogen activators, summarize the clinical data on plasminogen activator therapy for acute myocardial infarction, and examine what conclusions can be drawn from the available clinical studies of streptokinase, t-PA, and APSAC. Because a complete understanding of the potential advantages of new plasminogen activators requires a knowledge of their structural and biochemical properties, we also discuss how an understanding of these properties has allowed modifications of available molecules. Finally, we turn our attention to the fibrin selectivity of plasminogen activators as a model of an intrinsic property of certain naturally occurring proteins and as a property that can be enhanced through the methods of protein engineering.
Basic Aspects of Thrombolysis and
Role of Plasminogen The enzyme pivotal to fibrinolysis in humans is plasmin. Plasmin is a fully active serine protease formed by the action of plasminogen activators on its zymogen precursor, plasminogen. Although plasmin's favored substrate is fibrin (which forms the structural framework of thrombi), plasmin is not a very selective enzyme. It also degrades circulating fibrinogen, clotting factors V and VIII,5 and platelet membrane receptors (thereby altering platelet function).
Plasminogen can be found both free in the circulation and bound to fibrin. When t-PA and scu-PA were discovered to possess intrinsic fibrin selectivity, it was reasoned that if the action of plasmin were largely confined to the thrombus, circulating plasma proteins would be spared, a lytic state would be avoided, and the ,probability of hemorrhage would diminish. As will become apparent later in this review, the validity of this hypothesis is not universally accepted.
Clinical studies have been conducted with singleand two-chain t-PA.10 11 Both forms are present in the circulation, and both can be produced in large quantities. Cleavage by plasmin of single-chain t-PA between amino acids Arg275 and lle276 produces two-chain t-PA. There is no change in molecular size, and two-chain t-PA is similar in fibrin selectivity and catalytic activity (in vivo) to its singlechain precursor.
Urokinase is also synthesized and secreted by endothelial cells as a single polypeptide chain of 54,000 Da (scu-PA). Unlike single-chain t-PA, scu-PA does not possess plasminogen activator activity. Cleavage by plasmin between amino acids Lys'58 and lle159
activates the molecule but does not reduce its molecular size because the two constituent chains continue to be associated by a disulfide bond. Urokinase was first studied clinically in the low molecular weight, 33,000-Da form (a proteolytic fragment of two-chain 55,000-Da urokinase). Unlike scu-PA, neither high nor low molecular weight two-chain urokinase possesses fibrin selectivity or resistance to plasminogen activator inhibitors; consequently, both forms of twochain urokinase must be considered first-generation plasminogen activators.
Streptokinase has now been chemically modified to form a third-generation plasminogen activator that has an increased fibrin specificity and a prolonged half-life in plasma. 12 The plasminogenstreptokinase complex was formed in vitro, and then an essential serine in the catalytic site of plasminogen was acylated. APSAC does not possess enzymatic activity, but its plasminogen component is capable of binding to fibrin. Once bound to fibrin, deacylation occurs. Deacylation then enables the complex to activate other plasminogen molecules. APSAC was designed with two potential advantages in mind. First, it was hoped that the enzymatically inactive, acylated molecule would rapidly bind to fibrin, thereby bypassing the activation of circulating plasminogen. Once APSAC was associated with fibrin, deacylation would then permit the activation of fibrin-bound plasminogen, concentrating fibrinolysis at the clot and thereby spar-ing circulating plasma proteins. In animal models in which fibrinogen sparing was used as a measure of fibrin selectivity, APSAC was significantly more fibrin-specific than urokinase or streptokinase but less so than t-PA.12 APSAC's second putative advantage over any of the available plasminogen activators is its longer half-life, which permits the administration of a thrombolytic dose in a single injection.
Pharmacologic Effects of Plasminogen Activators
Each plasminogen activator has a unique pharmacologic profile. Their physical half-lives in the human circulation cover a wide range. The half-lives of t-PA and scu-PA are very short (6 and 7 minutes, respectively'1'9), those of urokinase and streptokinase intermediate (16 and 23 minutes, respectively13"12) , and that of APSAC rather long (90 minutes'2). Functional half-life is equally as important as physical half-life. t-PA and two-chain urokinase are readily and irreversibly inhibited in the circulation by plasminogen activator inhibitor I. scu-PA, before conversion to two-chain urokinase, is resistant to the plasma inhibitors plasminogen activator inhibitor I, a2-antiplasmin, and a2-macroglobulin. Streptokinase, a bacterial protein, has no plasma inhibitors. Because APSAC contains modified streptokinase, it also cannot be inhibited directly.
The plasmin ultimately generated by the action of any plasminogen activator is susceptible to inhibition by a2-antiplasmin. The Knowledge of the functional organization of scu-PA is less complete. The A chain of scu-PA contains, in addition to an EGF-like domain, a single kringle region that is considerably homologous with the kringles of t-PA (even though scu-PA does not appear to bind fibrin).39, 40 The B chain of scu-PA contains the catalytic portion of the molecule. As indicated above, an important property that differentiates scu-PA from t-PA is scu-PA's resistance to irreversible inhibition by plasminogen activator inhibitor I (and to other plasminogen activator inhibitors). Therefore, unlike t-PA, scu-PA is stable in human plasma for extended periods. (Plasminogen activator inhibitor I binds reversibly to scu-PA: when scu-PA forms a ternary complex with fibrin and plasminogen, plasminogen activator inhibitor I is displaced.) Whether this resistance to inhibition resides in the A or B chain of scu-PA is not clear; however, it has been demonstrated that the catalytic site becomes susceptible to irreversible inhibition after plasmin cleaves scu-PA between residues Lys'58 and Ile'59.
Modification of Native Plasminogen Activators by Recombinant DNA Methods
Because scu-PA is quite resistant to inhibition by plasminogen activator inhibitor I (a feature unique to scu-PA), considerable effort has been dedicated to elucidating and manipulating the mechanism of this resistance to inhibition. To this end, Stump et a141 initially described a low molecular weight form of scu-PA that has subsequently been produced by recombinant DNA methods.42 This low molecular weight scu-PA contains amino acids 144 to 411 of the full-length molecule. It retains, however, the full-length molecule's fibrin selectivity and resistance to plasminogen activator inhibitor I. In another approach, Nelles et a143 attempted to prevent the conversion of single-chain urokinase to two-chain urokinase by mutating the Lys"8-Ile'9 peptide bond. Either Gly or Glu was substituted for Lys'8 by site-directed mutagenesis. Although the two mutant proteins could not be converted to two-chain urokinase, their Km for activation of plasminogen was much lower than that of native scu-PA, suggesting that the conversion to two-chain urokinase is important for optimal function in fibrinolysis.
Approaches to Increasing Fibrin Selectivity
Addition of Fibrin-Binding Domains to Native
Plasminogen Activators
Once it became clear that plasminogen activators could be modified at specific sites in their structures, several laboratories began designing hybrid plasminogen activators that combined the desirable properties of two or more molecules. Robbins and coworkers44,45 attempted to add increased fibrinbinding ability to plasminogen activators by preparing hybrids combining the fibrin-binding domain of plasminogen and either the catalytic domain of urokinase or the catalytic domain of t-PA. The two parent molecules were linked chemically by formation of a disulfide bond. Robbins and coworkers demonstrated that fibrin-binding domains could be appended to either urokinase or t-PA; however, the fibrinolytic potency of the hybrids was no greater than that of native scu-PA or t-PA.
Nelles et a142 used the tools of molecular biology to approach the problem of increasing fibrin selectivity. They constructed a recombinant hybrid protein containing the A chain (fibrin-binding domain) of t-PA and the low molecular weight form of scu-PA. They spliced the cDNA for t-PA, which encodes the 5' untranslated region and amino acids Ser' through Thr263, to the cDNA for low molecular weight scu-PA, which codes for Leu '44 through Leu411, and then expressed the hybrid DNA in Chinese hamster ovary cells. The fibrin-binding activity of this recombinant hybrid plasminogen activator was significantly less than that of native t-PA, as was its fibrinolytic potency. Antibody- Targeted Our laboratory has taken another approach that uses bifunctional antibodies (with dual specificity for fibrin and a plasminogen activator) to increase the concentration of plasminogen activator in the proximity of fibrin. It was hoped that this approach could be used to increase the potency of intrinsic plasminogen activators already present in the circulation. Hybrid Molecules Containing an Antifibrin Antibody and a Plasminogen Activator
Chemically conjugated model compounds have been assembled by linking antifibrin antibody 59D8 (or its Fab) to urokinase or t-PA by means of the disulfide cross-linking reagent N-succinimidyl 3-(2-pyridyldithio)propionate.47, 48 The urokinase-59D8 and t-PA-59D8 conjugates were significantly more potent than either urokinase or t-PA in several in vitro assays48 and in vivo in the rabbit jugular vein model. 49 The activity of the model compounds was also highly specific in vitro and in vivo, and the increase in fibrinolytic potency was accompanied by a decrease in the degradation of plasminogen, a2-antiplasmin, and fibrinogen.
With and 1%; mortality from the infarction itself is only about 10%. It must be established whether hemorrhage is an intrinsic risk of fibrinolytic therapy, regardless of the selectivity of the agent used, or whether increased selectivity for a component of the thrombus is of value in diminishing hemorrhagic complications. Fibrin-selective and nonselective plasminogen activators are now being rigorously compared in large multicenter trials, and it would seem prudent to await the results of the ISIS-III and GISSI-JI studies. These studies address not only the relative merits of the agents being tested but also the desirability of designing and clinically testing newer agents, agents in which selectivity for a component of the thrombus is further increased.
Our bias is that selectivity will be recognized as a desirable property. The ideal plasminogen activator would be designed to recognize the coronary thrombus, to act locally in lysing it, and to then be eliminated or inactivated without generally perturbing the hemostatic system. Although some available agents possess various degrees of fibrin selectivity, all have at times caused a lytic state (with extensive loss of clotting proteins), and all have caused serious hemorrhage. Can the coronary thrombus be differentiated from thrombi in other sites? Is cerebral hemorrhage really related to thrombolysis? Or is some other process more indirectly related to the loss of an intact hemostatic system responsible? When these questions are answered, the tools of protein engineering can be used to create molecules that have optimal properties with regard to both recognition of components of the thrombus and duration of action. For example, it may be possible to differentiate between recently formed and older thrombi on the basis of relative degrees of fibrin cross-linking. One would hope that a coronary thrombus that is characterized by acute ischemic pain would be of more recent origin than a silent fibrin plug that holds back potential bleeding. Those components that have been modified by the clotting process offer the most easily defined targets toward which to direct a clot-selective agent. Fibrin, which differs in its covalent structure from its circulating precursor fibrinogen, is one obvious choice. Alternative targets include platelets altered during the clotting process, epitopes comprising the junction between platelet receptors and the proteins that bind to them (such as von Willebrand's factor, fibrinogen, and fibronectin28-30), and the covalent link between a2-antiplasmin and fibrin. There is also a growing understanding of the determinants that govern the clearance of a protein from the circulation. By appropriate engineering, it may also be possible to impart a circulatory half-life that is consistent with the therapeutic goals of clot dissolution and prevention of reocclusion yet avoids the risk of an excessively long impairment of the hemostatic system.
